natgillin/translations-raw huggingface dataset:
Ikke-adenocarcinoma 
Non-adenocarcinoma
Brug ikke lægemidlet efter den udløbsdato, der står på æsken, blisterpakningen og folieindpakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton, blister and overwrap foil after EXP.
CYP2D6's rolle i den metaboliske clearance af gefitinib er blevet evalueret i et klinisk forsøg med raske frivillige, der var genotypebestemt for CYP2D6. 
The role of CYP2D6 in the metabolic clearance of gefitinib has been evaluated in a clinical trial in healthy volunteers genotyped for CYP2D6 status.
Metaboliseringen af gefitinib sker via cytokrom P450-isoenzymerne CYP3A4 (overvejende) og CYP2D6. 
The metabolism of gefitinib is via the cytochrome P450 isoenzyme CYP3A4 (predominantly) and via CYP2D6.
Gefitinib er undersøgt i et klinisk forsøg, der blev udført på 41 patienter med solide tumorer og normal leverfunktion eller moderat eller svær nedsat leverfunktion (klassificeret i henhold til grader af baseline Common Toxicity Criteria for AST, basisk phosphatase og bilirubin) på grund af levermetastaser. 
Gefitinib has been evaluated in a clinical trial conducted in 41 patients with solid tumours and normal hepatic function, or moderate or severe hepatic impairment (classified according to baseline Common Toxicity Criteria grades for AST, alkaline phosphatase and bilirubin) due to liver metastases.
<0,0001 4,4 gange højere hos dem med adenokarcinom end hos dem, der ikke har adenokarcinom 
Histology <0.0001 4.4 times higher in adenocarcinoma than in non-adenocarcinoma
Pankreatit Gastrointestinal perforation 
Pancreatitis Gastrointestinal perforation
Ud fra tilgængelige data er der ikke tegn på, at disse in vitro-resultater har nogen kliniske konsekvenser. 
Available data do not suggest any clinical consequences to this in vitro finding.
IRESSA indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. den er i det væsentlige natriumfri. 
IRESSA contains less than 1 mmol (23 mg) of sodium per tablet, that is to say it is essentially ‘sodium-free.'
Patienter, der tåler bivirkningerne diarré eller hudreaktioner dårligt, kan håndteres ved at foretage et kort behandlingsophør (op til 14 dage), hvorefter behandling med doseringen på 250 mg genoptages (se pkt. 
Patients with poorly tolerated diarrhoea or skin adverse reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg dose (see section 4.8).
Effekten opnåede statistisk signifikans for hunmus, men ikke for hanmus. 
The effects reached statistical significance for the female mice, but not for the males.
IFUM-studiet var et enkeltarmet multicenter-studie, der blev gennemført med kaukasiske patienter (n=106) med følsom NSCLC med aktiverede EGFR-mutationer for at bekræfte, at aktiviteten af gefitinib er ens i kaukasiske og asiatiske populationer. 
The IFUM study was a single-arm, multicentre study conducted in Caucasian patients (n=106) with activating, sensitising EGFR mutation positive NSCLC to confirm that the activity of gefitinib is similar in Caucasian and Asian populations.
Den objektive responsrate (ORR) hos de patienter, som var tumor- og ctDNA-mutationspositive, var 77 % (95 % CI: 66 % til 86 %) og 60 % (95 % CI: 44 % til 74 %) hos dem, som kun var tumormutationspositive. 
The objective response rate (ORR) in those patients who were tumour and ctDNA mutation positive was 77% (95% CI: 66% to 86%) and in those who were tumour only mutation positive 60% (95% CI: 44% to 74%).
Der er ikke påvist nogen relevant klinisk aktivitet hos patienter med kendt EGFRmutationsnegative tumorer. 
No clinically relevant activity has been shown in patients with known EGFR mutation-negative tumours.
Tabel 7 Opsummering af multivariat logistisk regressionsanalyse for at identificere faktorer, som uafhængigt forudsiger tilstedeværelsen af EGFR-mutationer hos 786 kaukasiske patienter* Faktorer som forudsiger tilstedeværelse af EGFRmutation p-værdi 
Table 7 Summary of multivariate logistic regression analysis to identify factors that independently predicted for the presence of EGFR mutations in 786 Caucasian patients*
En sådan forøgelse kan potentielt være relevant for CYP2D6-substrater med et snævert terapeutisk vindue. 
Such an increase might potentially be relevant for CYP2D6 substrates with narrow therapeutic index.
Tal i kvadratiske parenteser er 95 % konfidensinterval (CI) for HR. N Antal randomiserede patienter. 
Numbers in square brackets are 95% confidence intervals for HR N Number of patients randomised.
Patienter med moderat til svær nedsat leverfunktion (Child-Pugh B eller C) som følge af cirrose har forøgede plasmakoncentrationer af gefitinib. 
Patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to cirrhosis have increased plasma concentrations of gefitinib.
Hver tablet indeholder 3,86 mg natrium. 
Each tablet contains 3.86 mg of sodium.
In vitro-data indikerer, at gefitinib er et substrat for membrantransportproteinet Pg-p. 
In vitro data indicate that gefitinib is a substrate for the membrane transport protein P-gp.
Spørg din læge eller apoteket til råds, før du tager nogen form for medicin, hvis du er gravid, har chance for at blive gravid, eller hvis du ammer. 
Talk to your doctor before taking this medicine if you are pregnant, may become pregnant or are breast-feeding.
Primært endepunkt total overlevelse abc 
Primary endpoint overall survival abc
Det randomiserede fase III-forsøg ISEL blev gennemført med patienter med avanceret NSCLC, som tidligere havde modtaget 1 eller 2 gange kemoterapiregimer, og som var refraktære eller intolerante over for det sidste modtagne regime. 
The randomised phase III ISEL study was conducted in patients with advanced NSCLC who had received 1 or 2 prior chemotherapy regimens and were refractory or intolerant to their most recent regimen.
I et klinisk forsøg hos patienter blev gefitinib givet sammen med metoprolol (et CYP2D6-substrat). 
In a clinical trial in patients, gefitinib was co-administered with metoprolol (a CYP2D6 substrate).
Hvor det er muligt, er frekvenserne baseret på forekomsten af sammenlignelige bivirkningsrapporter ud fra et samlet datasæt fra fase III-studierne ISEL, INTEREST og IPASS (2.462 IRESSA-behandlede patienter). 
Adverse reactions have been assigned to the frequency categories in Table 1 where possible based on the incidence of comparable adverse event reports in a pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 IRESSA-treated patients).
Der findes kun begrænsede data for patienter med kreatininclearance ≤ 20 ml/min, og derfor anbefales det, at der udvises forsigtighed over for disse patienter (se pkt. 
Only limited data are available in patients with creatinine clearance  20 ml/min and caution is advised in these patients (see section 5.2).
Det randomiserede fase III-forsøg INTEREST blev gennemført hos patienter med lokal-avanceret eller metastatisk NSCLC, der tidligere har fået platinbaseret kemoterapi. 
The randomised phase III INTEREST study was conducted in patients with locally advanced or metastatic NSCLC who had previously received platinum-based chemotherapy.
Den anbefalede dosering af IRESSA er én tablet a 250 mg én gang dagligt. 
The recommended posology of IRESSA is one 250 mg tablet once a day.
Ved denne form for kræftsygdom dannes der ondartede (kræft)celler i lungevævet. 
This cancer is a disease in which malignant (cancer) cells form in the tissues of the lung.
Det vides ikke, om gefitinib udskilles i modermælk. 
It is not known whether gefitinib is secreted in human milk.
I et fase-I/II-studie, som undersøgte brug af gefitinib og stråling hos pædiatriske patienter med nyligt diagnosticeret hjernestammegliom eller ufuldstændig frastødning af supratentorielt malignt gliom, blev der rapporteret fire tilfælde (ét fatalt) af blødning i centralnervesystemet (CNS) ud af 45 indrullerede patienter. 
In a phase I/II trial studying the use of gefitinib and radiation in paediatric patients, with newly diagnosed brain stem glioma or incompletely resected supratentorial malignant glioma, 4 cases (1 fatal) of Central Nervous System (CNS) haemorrhages were reported from 45 patients enrolled.
I det samlede datasæt fra de kliniske fase III-forsøg ISEL, INTEREST og IPASS (2462 IRESSAbehandlede patienter) er de hyppigst rapporterede bivirkninger, der forekommer hos mere end 20 % af patienterne, diarré og hudreaktioner (omfattende hududslæt, akne, tør hud og kløe). 
In the pooled dataset from the ISEL, INTEREST and IPASS phase III clinical trials (2462 IRESSA-treated patients), the most frequently reported adverse drug reactions (ADRs), occurring in more than 20% of the patients, are diarrhoea and skin reactions (including rash, acne, dry skin and pruritus).
• Allergisk reaktion (almindelig), specielt hvis du får hævet ansigt, læber, tunge eller hals, du har svært ved at synke, nældefeber og har svært ved at trække vejret. 
Allergic reaction (common), particularly if symptoms include swollen face, lips, tongue or throat, difficulty to swallow, hives, nettle rash and difficulty breathing.
Interstitiel lungesygdom (ILS) 
Interstitial lung disease (ILD)
Gefitinib bindes til serumalbumin og surt -1- -glykoprotein. 
Gefitinib binds to serum albumin and alpha 1-acid glycoprotein.
Gefitinib er en selektiv lav-molekylær hæmmer af EGFR-tyrosinkinasen og er en effektiv behandling af patienter med tumorer med aktiverede mutationer af EGFR-tyrosinkinasedomæner uanset behandlingslinje. 
Gefitinib is a selective small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase and is an effective treatment for patients with tumours with activating mutations of the EGFR tyrosine kinase domain regardless of line of therapy.
I et åbent fase I-forsøg med en enkeltdosis 250 mg gefitinib til patienter med let, moderat eller svær hepatisk insufficiens på grund af cirrose (ifølge Child-Pugh klassifikationen) var der en forøget eksponering hos alle patientgrupper sammenlignet med den raske kontrolgruppe. 
In a phase I open-label study of single dose gefitinib 250 mg in patients with mild, moderate or severe hepatic impairment due to cirrhosis (according to Child-Pugh classification), there was an increase in exposure in all groups compared with healthy controls.
Lactosemonohydrat Cellulose, mikrokrystallinsk (E460) Croscarmellosenatrium Polyvidon (K29-32) (E1201) Natriumlaurilsulfat Magnesiumstearat 
Lactose monohydrate Microcrystalline cellulose (E460) Croscarmellose sodium Povidone (K29-32) (E1201) Sodium laurilsulfate Magnesium stearate
Yderligere et tilfælde af blødning i centralnervesystemet er rapporteret hos et barn med et ependymom fra et forsøg med gefitinib alene. 
A further case of CNS haemorrhage has been reported in a child with an ependymoma from a trial with gefitinib alone.
In vitro-studier har vist, at gefitinib har begrænset potentiale for at hæmme CYP2D6. 
In vitro studies have shown that gefitinib has limited potential to inhibit CYP2D6.
De fundne nul-effekt-niveauer i både mus og rotter var ikke højere end dem, der ses ved klinisk eksponering. 
At no-effect levels in both mice and rats there was no margin in clinical exposure.
Risikoen for dødelighed blandt patienter, der udviklede ILS, efter behandling med IRESSA eller kemoterapi, var højere hos patienter med følgende risikofaktorer: Rygning, reduceret normalt lungevæv ( 50 %) dokumenteret ved CT-scanning, tidligere ILS, ældre patienter ( 65 år gammel) og udtalte områder med pleural adhærence ( 50 %). 
Risk of mortality among patients who developed ILD on IRESSA or chemotherapy was higher in patients with the following risk factors: smoking, CT scan evidence of reduced normal lung (≤ 50%), pre-existing ILD, older age (≥ 65 years old), and extensive areas adherent to pleura (≥ 50%).
I IFUM-studiet blev mutationsstatus vurderet i tumor- og ctDNA-prøver indsamlet fra plasma under anvendelse af Therascreen EGFR-RGQ-PCR-sættet (Qiagen). 
In the IFUM trial, mutation status was assessed in tumour and ctDNA samples derived from plasma, using the Therascreen EGFR RGQ PCR kit (Qiagen).
Der anbefales ingen specifik dosisjustering hos patienter med ringe CYP2D6-aktivitet (poor metabolisers), men disse patienter bør monitoreres tæt for bivirkninger (se pkt. 
No specific dose adjustment is recommended in patients with known CYP2D6 poor metaboliser genotype, but these patients should be closely monitored for adverse events (see section 5.2).
a Værdier for IRESSA versus placebo. 
a Values presented are for IRESSA versus placebo.
Et ILS-tilfælde var fatalt, og dette forekom hos en patient, der fik gefitinib. 
One ILD-type event was fatal, and this occurred in a patient receiving gefitinib.
Aktive substanser der kan øge gefitinibs plasmakoncentration In vitro-studier har vist, at gefitinib er et substrat for p-glycoprotein (Pgp). 
Active substances that may increase gefitinib plasma concentrations In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp).
Når brug af CYP2D6-substrater overvejes samtidig med gefitinib, bør det overvejes at ændre dosis af CYP2D6-substratet, specielt for præparater med et snævert terapeutisk vindue. 
When the use of CYP2D6 substrates are considered in combination with gefitinib, a dose modification of the CYP2D6 substrate should be considered especially for products with a narrow therapeutic window.
Meget almindelig Forøgelse af alaninaminotransferase, hovedsageligt let til moderat 
Elevations in alanine aminotransferase, mainly mild to moderate
En ILS-bivirkning var fatal, og den forekom hos en patient, der fik placebo. 
One ILD-type event was fatal, and this occurred in a patient receiving placebo.
IRESSA som monoterapi er indiceret til behandling af voksne patienter med lokalt avanceret eller metastatisk ikke-småcellet lungecancer (NSCLC) med aktiverede EGFR-TK-mutationer (se pkt. 
IRESSA is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (see section
Data fra prækliniske (in vitro) forsøg indikerer, at gefitinib potentielt kan hæmme den kardielle aktionspotentiale-repolariseringsproces (fx QT-interval). 
Data from non-clinical (in vitro) studies indicate that gefitinib has the potential to inhibit the cardiac action potential repolarisation process (e.g. QT interval).
Hos patienter med positivt testresultat for EGFR-mutation var der signifikant flere IRESSA-behandlede patienter, som oplevede en forbedring i livskvalitet og symptomer på lungecancer i forhold til dem, der blev behandlet med carboplatin/paclitaxel (se tabel 4). 
In EGFR mutation-positive patients, significantly more IRESSA-treated patients experienced an improvement in quality of life and lung cancer symptoms vs. carboplatin/paclitaxel (see Table 4).
• Øjenproblemer (ikke almindelig), såsom smerte, røde øjne, øjne der løber i vand, lysfølsomhed, forandret syn eller indgroede øjenvipper. 
Eye problems (uncommon), such as pain, redness, watery eyes, light sensitivity, changes in vision or ingrowing eyelashes.
6.2 v. 7.3 Total 42.9 v. 20.0 EGFR-mutation+ 
42.9 v. 20.0 EGFR Mutation+
• Hudreaktioner såsom akne-lignende udslæt, som til tider er kløende og med tør og/eller sprukken hud 
Skin reactions such as an acne-like rash, which is sometimes itchy with dry and/or cracked skin
30 filmovertrukne tabletter. 
30 film-coated tablets.
Der har været isolerede rapporter af leversvigt, som i nogle tilfælde var letal. 
There have been isolated reports of hepatic failure which in some cases led to fatal outcomes.
Sådan skal du tage IRESSA 
How to take IRESSA
Gefitinib er kontraindiceret under ammeperioden, og derfor skal amning ophøre under gefitinib-behandling (se pkt. 
Gefitinib is contraindicated during breast-feeding and therefore breast-feeding must be discontinued while receiving gefitinib therapy (see section 4.3).
Interstitiel lungesygdom (1,3 %), ofte svær (CTC grad 3-4). 
Interstitial lung disease (1.3%), often severe (CTC grade 3-4).
Progressionsfri overlevelse ab 
Progression-free Survival
Kontakt lægen eller apotekspersonalet, før du tager IRESSA: - hvis du nogensinde har haft andre problemer med lungerne. 
Warnings and precautions Talk to your doctor or pharmacist before taking IRESSA if you have ever had any other lung problems.
I et japansk farmakoepidemiologisk studie hos 3.159 NSCLC-patienter, der blev fulgt i 12 uger, mens de fik gefitinib eller kemoterapi, fandt man følgende risikofaktorer for at udvikle ILS (uanset om patienterne blev behandlet med gefitinib eller kemoterapi): Rygning, dårlig performance status (PS  2), reduceret normalt lungevæv ( 50 %) dokumenteret ved CT-scanning, nylig diagnosticeret NSCLC (< 6 måneder), tidligere ILS, ældre ( 55 år gammel) og samtidig hjertesygdom. 
In a Japanese pharmacoepidemiological case control study in 3,159 patients with NSCLC receiving gefitinib or chemotherapy who were followed up for 12 weeks, the following risk factors for developing ILD (irrespective of whether the patient received IRESSA or chemotherapy) were identified: smoking, poor performance status (PS ≥ 2), CT scan evidence of reduced normal lung (≤ 50%), recent diagnosis of NSCLC (< 6 months), pre-existing ILD, older age (≥ 55 years old) and concurrent cardiac disease.
HR 0,68 [0,58 til 0,81] 6,6 m vs. 5,8 m p<0,0001 
HR 0.68 [0.58 to 0.81] 6.6 m vs 5.8 m p<0.0001
QoL Livskvalitet (Quality of life) FACT-L Functional assessment of cancer therapy-lung LCS Lungecancer subskala 
FACT-LFunctional assessment of cancer therapy-lung LCS Lung cancer subscale
Forekomsten af ILS blandt de asiatiske patienter, der fik enten gefitinib eller placebo, var henholdsvis ca. 3 % og 4 %. 
The majority of ILD-type events reported was from patients of Asian ethnicity and the ILD incidence among patients of Asian ethnicity receiving gefitinib therapy and placebo was approximately 3% and 4% respectively.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Dog sås der en reduceret fostervægt hos kaniner ved dosering af 20 mg/kg/dag og derover. 
However, in the rabbit, there were reduced foetal weights at 20 mg/kg/day and above.
Hver tablet indeholder 250 mg gefitinib. 
Each tablet contains 250 mg gefitinib.
Samtidig administration af gefitinib og ranitidin i en dosis, der forårsagede vedvarende forhøjet gastrisk pH ≥ 5, resulterede i en gennemsnitlig reducering af gefitinibs AUC på 47 % hos raske frivillige (se pkt. 
Concomitant administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥ 5 resulted in a reduced mean gefitinib AUC by 47% in healthy volunteers (see section 4.4 and 5.2).
Andel af tumor M-, der er M- i ctDNA) 
Proportion of tumour M- that are Mby ctDNA)
Eksponeringsgraden af gefitinib var bred, og overlappede hos både dem, der havde en normal metabolisme og dem, der havde nedsat metabolisme, men den gennemsnitlige eksponering af gefitinib var 2 gange højere hos gruppen af personer med dårlig metabolisme. 
The levels of exposure to gefitinib achieved in both the extensive and the poor metaboliser groups were wide and overlapping but the mean exposure to gefitinib was 2-fold higher in the poor metaboliser group.
• Tørre, røde og kløende øjne 
Dry, red or itchy eyes
In vitro-data indikerer, at CYP34A og CYP2D6 er de CYP-isozymer, der overvejende er involveret i den oxidative metabolisering af gefitinib. 
In vitro data indicate that CYP3A4 and CYP2D6 are the major P450 isozyme involved in the oxidative metabolism of gefitinib.
Hepatocellulære adenomer sås også i et 2årigt carcinogenicitetsstudie med mus, som viste en let forøget forekomst i hanmus ved middel dosis og i både han- og hunmus ved den høje dosis. 
The hepatocellular adenomas were also seen in a 2-year carcinogenicity study in mice, which demonstrated a small increased incidence of this finding in male mice at the mid dose, and in both male and female mice at the highest dose.
- hvis du ammer. 
if you are breast-feeding.
• Øvrige indholdsstoffer (hjælpestoffer): lactosemonohydrat; mikrokrystallinsk cellulose (E460); croscarmellosenatrium; povidon (K29-32) (E1201); natriumlaurilsulfat; magnesiumstearat; hypromellose (E464); macrogol 300; titandioxid (E171); jernoxid, gul (E172) og jernoxid, rød (E172). 
The other ingredients (excipients) are lactose monohydrate, microcrystalline cellulose (E460), croscarmellose sodium, povidone (K29-32) (E1201), sodium laurilsulfate, magnesium stearate, hypromellose (E464), macrogol 300, titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172).
Hos individuelle patienter med ringe metabolisme via CYP2D6 kan behandling med en potent CYP3A4-hæmmer medføre øgede plasmaniveauer af gefitinib. 
In individual patients with CYP2D6 poor metaboliser genotype, treatment with a potent CYP3A4 inhibitor might lead to increased plasma levels of gefitinib.
Interstitiel lungesygdom (ILS) er forekommet hos 1,3 % af patienterne, ofte i alvorlig grad (CTC grad 3-4). 
Interstitial lung disease (ILD) has occurred in 1.3% of patients, often severe (CTC grade 3-4).
Plasmakoncentrationerne var ikke forhøjede hos patienter med forhøjet aspartataminotransferase (ASAT), basisk fosfatase eller bilirubin på grund af levermetastaser (se pkt. 
Plasma concentrations were not increased in patients with elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to liver metastases (see section 5.2).
Den er 14 gange mindre potent end gefitinib til at hæmme EGFR-stimuleret cellevækst, og har ingen hæmmende effekt på tumorcellevækst i mus. 
The major metabolite identified was O-desmethyl gefitinib, which is 14-fold less potent than gefitinib at inhibiting EGFR stimulated cell growth and has no inhibitory effect on tumour cell growth in mice.
Hvis du har glemt at tage en tablet, skal du gøre som beskrevet nedenfor (afhængig af hvor længe, der er til næste dosis): 
If you forget to take IRESSA What to do if you forget to take a tablet depends on how long it is until your next dose.
• Blødning (såsom næseblod eller blod i urinen) 
Bleeding (such as nose bleed or blood in your urine) Protein in your urine (shown in a urine test)
Hvis du har problemer med at sluge tabletten, kan den opslæmmes i et halvt glas vand (uden brus). 
If you have trouble swallowing the tablet, dissolve it in half a glass of still (non-fizzy) water.
Hud og subkutane væv Meget almindelig Hudreaktioner, hovedsageligt let eller moderat (CTC grad 1 eller 2) pustuløst udslæt, til tider kløende med tør hud, inklusive hudfissurer, på erytematøs basis 
Skin reactions, mainly a mild or moderate (CTC grade 1 or 2) pustular rash, sometimes itchy with dry skin, including skin fissures, on an erythematous base
IPASS-forsøget viste, at IRESSA var carboplatin/paclitaxel overlegen i forhold til PFS, ORR, QoL og mht. symptomlindring, uden at der var nogen signifikant forskel på den samlede overlevelse hos behandlingsnaive patienter med lokalt fremskredent eller metastatisk NSCLC, hvis tumorer indeholdt aktiverende mutationer af EGFR-tyrosinkinase. 
In the IPASS trial, IRESSA demonstrated superior PFS, ORR, QoL and symptom relief with no significant difference in overall survival compared to carboplatin/paclitaxel in previously untreated patients, with locally advanced or metastatic NSCLC, whose tumours harboured activating mutations of the EGFR tyrosine kinase.
Uden at knuse tabletten, puttes den i et halvt glas drikkevand. 
Without crushing it, the tablet should be dropped in half a glass of drinking water.
Lægemidler, som forårsager vedvarende forhøjet gastrisk pH, såsom protonpumpehæmmere og h2-antagonister kan reducere biotilgængeligheden og plasmakoncentrationen af gefitinib, og kan derfor reducere effekten. 
Medicinal products that cause significant sustained elevation in gastric pH, such as proton-pump inhibitors and h2-antagonists may reduce bioavailability and plasma concentrations of gefitinib and, therefore, may reduce efficacy.